Yahoo · Jun 11, 2026
When Should You Buy medmix AG (VTX:MEDX)?
While medmix AG ( VTX:MEDX ) might not have the largest market cap around , it saw significant share price movement...
NASDAQ · MEDX
Financial Services · Asset Management
$35.24
Down-$0.25 (-0.70%)
Updated Sep 20, 2026, 4:42 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
MEDX closed at $35.24 after 19 trading sessions, down 5.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $35.25 | $35.25 | $35.2363 | $35.2363 | 732.96 |
| Sep 17, 2026 | $35.33 | $35.4862 | $35.33 | $35.4862 | 361.8 |
| Sep 16, 2026 | $35.105 | $35.105 | $34.9905 | $34.9905 | 428.84 |
| Sep 15, 2026 | $34.99 | $35.04 | $34.9577 | $34.9577 | 588.8 |
| Sep 14, 2026 | $35.30 | $35.30 | $35.2891 | $35.2891 | 227.8 |
| Sep 11, 2026 | $35.10 | $35.10 | $34.9572 | $34.9572 | 1.89K |
| Sep 10, 2026 | $35.0604 | $35.0604 | $35.0604 | $35.0604 | 66.8 |
| Sep 9, 2026 | $35.465 | $35.465 | $35.16 | $35.2396 | 3.98K |
| Sep 8, 2026 | $35.60 | $35.60 | $35.33 | $35.4213 | 4.81K |
| Sep 4, 2026 | $36.825 | $36.825 | $36.52 | $36.6906 | 2.16K |
| Sep 3, 2026 | $37.08 | $37.0834 | $37.02 | $37.0834 | 1.92K |
| Sep 2, 2026 | $37.4899 | $37.4899 | $37.105 | $37.1775 | 1.3K |
| Sep 1, 2026 | $36.625 | $36.755 | $36.625 | $36.7543 | 4.44K |
| Aug 31, 2026 | $36.42 | $36.42 | $36.4038 | $36.417 | 1.62K |
| Aug 28, 2026 | $36.72 | $36.72 | $36.4218 | $36.5564 | 2.11K |
| Aug 27, 2026 | $37.09 | $37.10 | $36.865 | $36.8878 | 1.74K |
| Aug 26, 2026 | $37.335 | $37.335 | $37.26 | $37.2921 | 1.19K |
| Aug 25, 2026 | $37.33 | $37.865 | $37.33 | $37.8113 | 1.98K |
| Aug 24, 2026 | $37.55 | $37.55 | $37.225 | $37.4519 | 2.28K |
The latest Smart Investors Daily articles mentioning MEDX.
MEDX research
Company profile and research snapshot.
The fund is an actively-managed exchange-traded fund (“ETF”) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.
Consensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Jun 11, 2026
While medmix AG ( VTX:MEDX ) might not have the largest market cap around , it saw significant share price movement...
Zacks Investment Research · Jun 19, 2024
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Zacks Investment Research · Jun 22, 2023
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning MEDX.
No results
No recent SID articles mention MEDX.